WallStSmart

Edwards Lifesciences Corp (EW)vsKoninklijke Philips NV ADR (PHG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Koninklijke Philips NV ADR generates 183% more annual revenue ($17.83B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 5.0%. PHG appears more attractively valued with a PEG of 0.32. EW earns a higher WallStSmart Score of 61/100 (C+).

EW

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 7.5Value: 6.0Quality: 4.8
Piotroski: 2/9

PHG

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 5.0Value: 7.3Quality: 5.3
Piotroski: 6/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.9%)

Margin of Safety

+69.9%

Fair Value

$263.84

Current Price

$83.98

$179.86 discount

UndervaluedFair: $263.84Overvalued
PHGUndervalued (+3.8%)

Margin of Safety

+3.8%

Fair Value

$33.33

Current Price

$26.16

$7.17 discount

UndervaluedFair: $33.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW2 strengths · Avg: 9.0/10
Operating MarginProfitability
31.2%10/10

Strong operational efficiency at 31.2%

Revenue GrowthGrowth
16.7%8/10

16.7% revenue growth

PHG3 strengths · Avg: 8.7/10
PEG RatioValuation
0.3210/10

Growing faster than its price suggests

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.31B8/10

Generating 1.3B in free cash flow

Areas to Watch

EW3 concerns · Avg: 3.0/10
PEG RatioValuation
2.074/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
45.4x2/10

Premium valuation, high expectations priced in

PHG4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.1%4/10

1.1% revenue growth

Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

EPS GrowthGrowth
-0.5%2/10

Earnings declined 0.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.

Bull Case : PHG

The strongest argument for PHG centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.32 suggests the stock is reasonably priced for its growth.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 45.4x leaves little room for execution misses.

Bear Case : PHG

The primary concerns for PHG are Revenue Growth, Return on Equity, Profit Margin.

Key Dynamics to Monitor

EW profiles as a growth stock while PHG is a value play — different risk/reward profiles.

EW carries more volatility with a beta of 0.94 — expect wider price swings.

EW is growing revenue faster at 16.7% — sustainability is the question.

PHG generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

EW scores higher overall (61/100 vs 51/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Koninklijke Philips NV ADR

HEALTHCARE · MEDICAL DEVICES · USA

Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?